The IntegriCell™ solution aims to establish a standardized, integrated cryopreservation and distribution solution for the global Cell Therapy market. The IntegriCell™ solution combines• Cryoport’s global leadership in temperature-controlled supply chain solutions and storage• Cryopreservation experience and expertise• Leukapheresis collection capabilities via third-party strategic partnerships The goal is to streamline the complex processes necessary to treat an increasing number of patients with today's most advanced cell therapies, while ensuring the highest quality and safety standards.Cryoport is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research, clinical and commercial spectrum. With over 50 locations in 17 countries, Cryoport's global platform provides mission-critical solutions, services, and products to the Cell and Gene Therapy industry. Cryoport supports 670+ active Cell and Gene Therapy clinical trials, 80+ phase III regenerative medicine clinical trials, and 15 commercial Cell and Gene therapies.

Established in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients' lives worldwide.ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory, and Commercialization. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.

Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies that are more affordable and widely available to patients in need. With Cellares’ proprietary platform—the Cell Shuttle—biopharma companies, academic research centers, and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale.In this role I led Cellares’ business development and marketing teams. The focus was engaging with cell and gene therapy developers, creating awareness of our technology, and executing collaborative agreements to build long-term sales, and drive profitability. In 2020 we launched the Early Access Partnership Program (EAPP) and successfully added four organizations in 2020-2021. In 2022 we opened the Technology Adoption Program to work directly with cell therapy developers and transition manufacturing onto the Cell Shuttle platform.

Be The Match BioTherapies® (now NMDP Biotherapies) partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program® (NMDP)/Be The Match®, and have unparalleled experience managing cellular therapies. BTMB's cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a robust, customizable technology platform, MatchSource. BTMB's experience in cell sourcing and collection allows the organization to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through the NMDP's research program CIBMTR® (Center for International Blood and Marrow Transplant Research®).

Previously known as Progenitor Cell Therapies (PCT), now the global cell therapy CDMO service platform for Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS). HCATS is a leading external development and manufacturing partner that focuses exclusively on the cell therapy industry. In September of 2020 Hitachi Chemical's global regenerative medicine business was renamed Minaris Regenerative Medicine.

I led strategic and product marketing activities by vetting new business, product development opportunities and developing strategies for effective commercialization of these opportunities. Specific focus on gathering business intelligence and assessing market opportunities in the cancer immunotherapy market related to leukapheresis - Dendritic Cell, T-Cell and CAR-T cellular therapies. I also supervised the global product management team, responsible for product management activities, supporting commercial teams with protocol launches, data management and IT initiatives.In a previous role, I oversaw the global marketing effort and product launch of the Quantum Cell Expansion System. The Quantum was a novel automated system for growing adherent and suspension cells in a closed environment. The system was designed for multiple cell types and protocol flexibility. The system's unique controls streamline cell culture, delivered reproducible processes, and reduced the risk of contamination for large-scale clinical cell manufacturing.

I was the global platform lead for the newly launched apheresis system, the Spectra Optia. Other responsibilities included global marketing lead for the COBE Spectra Apheresis System (a medical device used for Peripheral Blood Stem Cell collection), the Elutra Cell Separation System (laboratory tool that separates cells based on size and density into multiple fractions) and the COBE 2991 Cell Processor (commonly used in blood, stem cell, and bone marrow washing and processing). In 2008 I launched the MNC collection protocol (peripheral blood stem cell collection) into Europe and Australia. U.S. , Canada, Latin America and Asia Pacific launches followed after clinical trial completion and regulatory approvals.